Zentiva Launches First Biosimilar Monoclonal Antibody Across EU

Dec 1, 2025
Zentiva has introduced its first biosimilar monoclonal antibody in the European Union, marking the company's entry into the biosimilars market following EMA approval.

Zentiva has launched its first biosimilar monoclonal antibody across the European Union after receiving approval from the European Medicines Agency, announced in a press release.

The biosimilar is used for treating bone-related diseases and was approved through the EMA's centralized procedure. Distribution to European markets will begin in December 2025.

This marks Zentiva's entry into the biosimilars segment as part of its broader strategy to expand beyond traditional generics. The company stated that the move supports sustainable growth in the biologics sector, one of the fastest-growing areas in pharmaceuticals.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.